Literature DB >> 30982715

A Prospective Cohort Study on the Effects of Geriatric Rehabilitation Following Acute Exacerbations of COPD.

Eléonore F van Dam van Isselt1, Monica van Eijk2, Nan van Geloven3, Karin H Groenewegen-Sipkema4, Jan-Willem K van den Berg5, Cécile M A Nieuwenhuys2, Niels H Chavannes2, Wilco P Achterberg2.   

Abstract

OBJECTIVES: Older patients with chronic obstructive pulmonary disease (COPD), hospitalized for an acute exacerbation, often do not receive recommended post-acute pulmonary rehabilitation. This underuse might be related to the impaired clinical and functional status of these patients, who are more likely to present with frailty, comorbidities, and disability. Having developed and implemented a geriatric rehabilitation program for these patients (GR_COPD), the primary aim of this study was to investigate the effectiveness of this program. DESIGN AND INTERVENTION: A prospective cohort study with a 3-month follow-up period. Patients who declined the GR_COPD program were considered as controls. SETTING AND PARTICIPANTS: The study was conducted at the pulmonary department of 2 hospitals. Patients were eligible when hospitalized as a result of an acute exacerbation of COPD and indicated for the GR_COPD program based on standardized criteria.
METHODS: Primary outcome was defined as change in disease-specific health status measured with the clinical COPD questionnaire (CCQ), secondary outcome as the exacerbation rate ratio during follow-up. To balance potential confounders between the intervention and control group, propensity score-based weighted linear regression analyses were performed.
RESULTS: Of the 158 included patients [78 (49.4%) male, mean age 70.8 (±8.1) years, mean forced expiratory volume in 1 second: 35.5 (±12.8) as % of predicted], 78 received the GR_COPD program. The results of the CCQ showed a significant and clinically relevant treatment effect of -0.56 points [95% confidence interval (CI) -0.89, -0.23; P = .001). Patients in the control group had 2.77 times more exacerbations compared with the intervention group (95% CI 2.13, 3.58; P < .001). CONCLUSIONS/IMPLICATIONS: This study shows a clinically relevant effect of the GR_COPD program on disease-specific health status and exacerbation rate. Implementation of the program for older patients with severe COPD hospitalized for an acute exacerbation is recommended.
Copyright © 2019 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COPD; Geriatric rehabilitation; health status; post-acute PR; propensity score

Year:  2019        PMID: 30982715     DOI: 10.1016/j.jamda.2019.02.025

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  4 in total

Review 1.  Improving Exercise-Based Interventions for People Living with Both COPD and Frailty: A Realist Review.

Authors:  Lisa Jane Brighton; Catherine J Evans; William D C Man; Matthew Maddocks
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-04-20

2.  Pan-European Study on Functional and Medical Recovery and Geriatric Rehabilitation Services of Post-COVID-19 Patients: Protocol of the EU-COGER Study.

Authors:  S Grund; M A A Caljouw; M L Haaksma; A L Gordon; R van Balen; J M Bauer; J M G A Schols; W P Achterberg
Journal:  J Nutr Health Aging       Date:  2021       Impact factor: 4.075

3.  Integrating Comprehensive Geriatric Assessment for people with COPD and frailty starting pulmonary rehabilitation: the Breathe Plus feasibility trial protocol.

Authors:  Lisa Jane Brighton; Catherine J Evans; Morag Farquhar; Katherine Bristowe; Aleksandra Kata; Jade Higman; Margaret Ogden; Claire Nolan; Deokhee Yi; Wei Gao; Maria Koulopoulou; Sharmeen Hasan; Claire J Steves; William D-C Man; Matthew Maddocks
Journal:  ERJ Open Res       Date:  2021-03-29

4.  Effect of respiratory rehabilitation training on elderly patients with COVID-19: A protocol for systematic review and meta-analysis.

Authors:  Huan Yan; Yonghong Ouyang; Lang Wang; Xiangjun Luo; Qian Zhan
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.